KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease

Approximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility in predicting long-term complications in SCD remains unclear. We investigated whether "Kidney Disease: Improving Global Outcomes (KDIGO)" algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 adults with SCD from 2 academic institutions. KDIGO criteria include UACR detected in 2 consecutive measurements ≥3 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow-up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a twofold greater risk of CKD progression and 1.8-fold greater risk of mortality (P ≤ .05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P ≤ .0087). Our data provide clinical support for the screening utility of UACR based on repeated abnormal values ≥3 months apart. The KDIGO heat map further refines the risk of long-term outcomes among adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-08-19
DOI
https://doi.org/10.1182/bloodadvances.2025017204
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease

Rima S. Zahr, Victor R. Gordeuk, Kristin Wuichet, Santosh L. Saraf et al.
Blood Advances
Hemoglobinopathies and Related Disorders
article

KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease

Rima S. Zahr, Victor R. Gordeuk, Kristin Wuichet, Santosh L. Saraf, Michael R. DeBaun, Mitchell J. Weiss, Zalaya Ivy, Xu Zhang, Alexander G. Bick
article en

Abstract

Approximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility in predicting long-term complications in SCD remains unclear. We investigated whether "Kidney Disease: Improving Global Outcomes (KDIGO)" algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 adults with SCD from 2 academic institutions. KDIGO criteria include UACR detected in 2 consecutive measurements ≥3 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow-up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a twofold greater risk of CKD progression and 1.8-fold greater risk of mortality (P ≤ .05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P ≤ .0087). Our data provide clinical support for the screening utility of UACR based on repeated abnormal values ≥3 months apart. The KDIGO heat map further refines the risk of long-term outcomes among adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.

Blood AdvancesVol. 9(21)
St. Jude Children's Research Hospital (US), University of Tennessee Health Science Center (US), Vanderbilt University (US), University of Illinois Chicago (US), University of Chicago (US), Vanderbilt University Medical Center (US)
Pfizer, Vertex Pharmaceuticals, Agios Pharmaceuticals, bluebird bio, Incyte, Novo Nordisk, National Institutes of Health
Good health and well-being
Openalex Percentile: Top 71%
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.